Validation of Amotosalen-HCI for Clinical Use
Validation of Amotosalen-HCI for Clinical Use
批准号:
6695071
负责人:
JOHN E HEARST
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-15 至 2004-01-14
中文摘要
说明书(申请人提供):阿莫沙林-HCI是CERUS公司拥有的一种专有补骨脂素化合物,用于灭活输血行业的病原体。盐酸阿莫他林用于光化学过程中,用于灭活浓缩血小板和新鲜冰冻血浆中的病原体。AIIgenic细胞免疫疗法(ACIT)是另一种需要盐酸阿莫多沙林的光化学疗法,在过去的5年里,Cerus公司一直在开发这种疗法。该计划的重点是解决不匹配干细胞移植中尚未满足的主要安全需求。ACIT已经产生了几篇来自美国血液学会的经典手稿和奖项,并在临床上进行了三项试验的调查。第一项研究于1998年12月30日首次提交美国食品及药物管理局(FDA),名为“人类白细胞抗原单倍型不匹配造血干细胞移植中经光化学处理的供体T细胞补充剂的I期研究”。第二项研究是由国家骨髓捐赠者计划提交给FDA的,并于2002年9月30日获得批准,这项研究是关于光化学处理的T细胞补充剂在无关供者PBSC移植中的1B期研究。第三项试验“用合成补骨脂素和紫外线A光(UV照明系统,CERUS)治疗自体EB病毒+淋巴母细胞系”,已由约翰霍普金斯医学院提交,并于61612002获得美国食品和药物管理局的批准。我们收到了更多关于使用阿莫他林光化学处理细胞进行新的临床试验的请求,以改进干细胞移植,开发疫苗,并促进光电泳法。ACIT技术满足了一个未得到满足的需求。ACIT技术的积极发展需要资金支持,不幸的是,目前的商业环境排除了CERUS公司提供足够内部支持的可能性。该第一阶段申请申请所需资金,用于在Cerus公司开发盐酸阿莫多沙林的GMP制剂。以前用于ACIT临床研究的配方不再生产,也不再得到支持。该申请申请了交叉研究所需的资金,该研究将验证一种用于非病原体灭活市场的临床研究中使用的盐酸阿莫他林的新配方。将需要进行广泛的稳定性研究来确定Cerus Amotosalen-HCI的充分性。
英文摘要
DESCRIPTION (provided by applicant): Amotosalen-HCI is a proprietary psoralen compound owned by Cerus Corporation, which has been developed for the inactivation of pathogens for the blood transfusion industry. Amotosalen-HCI is used in a photochemical process for the inactivation of pathogens in platelet concentrates and in fresh frozen plasma. AIIogeneic Cellular Immune Therapy (ACIT), another photochemical process requiring Amotosalen-HCI, has been in development at Cerus Corporation for the past 5 years. The program is focused on solving the major unmet need of safety in mismatched stem cell transplantation. ACIT has generated several classic manuscripts and awards from the American Society of Hematology and has been under investigation in the clinic in three trials. The first, "A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation," was first filed with the FDA on 12/30/98. The second, "A Phase 1B Study of Photochemically Treated T-cell Supplements in Unrelated Donor PBSC Transplantation," was filed with the FDA by the National Marrow Donor Program and approved on 9/30/02. The third trial, "Autologous EBV+ Lymphoblastoid Cell Line Treated with Synthetic Psoralen (Amotosalen-HCI) and Ultraviolet A Light (UV Illumination System, Cerus)," has been filed by Johns Hopkins School of Medicine and was approved by the FDA on 61612002. We have received additional requests for new clinical trials using Amotosalen Photochemically Treated cells for the improvement of stem cell transplantation, for the development of vaccines, and for facilitating photophoresis. ACIT technology fulfills an unmet need. ACIT technology needs financial support for its aggressive development, and unfortunately the present business climate has eliminated the possibility that there will be sufficient internal support from Cerus Corporation. This Phase I application requests the funds required for the development of a GMP formulation of Amotosalen-HCI at Cerus Corporation. The previously used formulation for prior ACIT clinical studies is no longer manufactured and can no longer be supported. This application requests the funds needed for a crossover study which will validate a new formulation of Amotosalen-HCI for use in clinical studies not directed at the pathogen inactivation market. Extensive stability studies will be required to determine the adequacy of the Cerus Amotosalen-HCI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Amotosalen PCT of Leukapheresis Units for GvHD Therapy
-
批准号:6787862
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2004
-
负责人:JOHN E HEARST
-
依托单位:
Amotosalen PCT of Leukapheresis Units for GvHD Therapy
-
批准号:7492433
-
项目类别:
-
资助金额:$26.28万
-
财政年份:2004
-
负责人:JOHN E HEARST
-
依托单位:
MINIATURIZED INSTRUMENTATION FOR THE HTS OF DNA REPAIR
-
批准号:6738364
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2004
-
负责人:JOHN E HEARST
-
依托单位:
Cord Blood Stem Cell Transplantation, Hemoglobinopathies
-
批准号:6689114
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2003
-
负责人:JOHN E HEARST
-
依托单位:
DNA Repair Inhibition and Cancer Therapy
-
批准号:6691226
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2003
-
负责人:JOHN E HEARST
-
依托单位:
Stem Cell Transplantation for Hemoglobinopathies in Dogs
-
批准号:6690207
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2003
-
负责人:JOHN E HEARST
-
依托单位:
STEM CELL TRANSPLANTATION--S-59 PHOTOCHEM T CELL
-
批准号:2908629
-
项目类别:
-
资助金额:$25.8万
-
财政年份:1999
-
负责人:JOHN E HEARST
-
依托单位:
STEM CELL TRANSPLANTATION WITH S-59 PHOTOCHEMICALLY TREA
-
批准号:6183982
-
项目类别:
-
资助金额:$25.8万
-
财政年份:1999
-
负责人:JOHN E HEARST
-
依托单位:
STEM CELL TRANSPLANTATION WITH S-59 PHOTOCHEMICALLY TREA
-
批准号:6390530
-
项目类别:
-
资助金额:$25.8万
-
财政年份:1999
-
负责人:JOHN E HEARST
-
依托单位:
STABLE AND DYNAMIC DNA SUPERCOILING IN VIVO
-
批准号:2185372
-
项目类别:
-
资助金额:$19.6万
-
财政年份:1992
-
负责人:JOHN E HEARST
-
依托单位:
STABLE AND DYNAMIC DNA SUPERCOILING IN VIVO
-
批准号:3307360
-
项目类别:
-
资助金额:$17.85万
-
财政年份:1992
-
负责人:JOHN E HEARST
-
依托单位:
STABLE AND DYNAMIC DNA SUPERCOILING IN VIVO
-
批准号:3307361
-
项目类别:
-
资助金额:$18.5万
-
财政年份:1992
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:2181123
-
项目类别:
-
资助金额:$12.42万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:2392075
-
项目类别:
-
资助金额:$22.43万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:2773891
-
项目类别:
-
资助金额:$1.25万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:3300397
-
项目类别:
-
资助金额:$17.46万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:3300394
-
项目类别:
-
资助金额:$21.59万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:2181124
-
项目类别:
-
资助金额:$20.92万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:2181122
-
项目类别:
-
资助金额:$17.6万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
DYNAMICS OF DNA MOTION AT PHYSIOLOGICAL CONCENTRATIONS
-
批准号:3300396
-
项目类别:
-
资助金额:$16.74万
-
财政年份:1989
-
负责人:JOHN E HEARST
-
依托单位:
海外基金